Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study

Journal of Mass Spectrometry

Volumn 39, Issue 12, 2004, Pages 1562-1569

  Do Carmo Borges, Ney Carter ^a   Mendes, Gustavo Duarte ^a,b   Borges, André ^a,b   De Oliveira, Sandro Evandir ^a,b   Barrientos Astigarraga, Rafael Eliseo ^b   De Nucci, Gilberto ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cartesius Development of Clinical Research   (Brazil)

Author keywords

Bioequivalence; Pharmacokinetics; Plasma; Ticlopidine

Indexed keywords

CALIBRATION; ETHERS; EXTRACTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ACIDIFIED PLASMA; HUMAN PLASMA; INTERNAL STANDARD (IS); LINEAR CALIBRATION;

PLASMAS;

CLOPIDOGREL; TICLOPIDINE;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; PLATELET AGGREGATION INHIBITORS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THERAPEUTIC EQUIVALENCY; TICLOPIDINE;

JONES;

EID: 10844278184     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.708     Document Type: Conference Paper

References (18)

1. Bruno JJ. The mechanisms of action of ticlopidine. Thromb. Res. Suppl. 1983; 4: 59.
2. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 2: 222.
3. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 8649(1): 1215.
4. Knudsen JB, Gormsen J. The effect of ticlopidine on platelet function in normal volunteers and in patients with platelet hyperaggregability in vitro. Thromb. Res. 1979; 16: 663.
5. Feliste R, Delebassee D, Simon MF, Chap H, Defreyn G, Vallee E, Douste-Blazy L, Maffrand JP. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb. Res. 1987; 4: 403.
6. Knudsen JB, Bastain W, Sefton CM, Allen JG, Dickinson JP. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992; 5: 579.
7. DiPerri T, Pasini FL, Frigerio C, Blardi P, Centini F, Messa GL, Ghezzi A, Volpi L. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration. Eur. J. Clin. Pharmacol. 1991; 5: 429.
8. Shah J, Fratis A, Ellis D, Murakami S, Teitelbaum P. Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J. Clin. Pharmacol. 1990; 8: 733.
9. Arnoux P, Sales Y, Mandray M, Lechat P, Berger Y, Cano JP. Quantitative high-performance liquid chromatographic, gas chromatographic, and gas chromatographic-mass spectrometric analysis of ticlopidine in baboon plasma after solid-phase extraction. J. Pharm. Sci. 1991; 11: 1092.
10. Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br. J. Clin. Pharmacol. 1991; 6: 761.
11. Itoh S, Suzuki S, Ando S, Funatsu Y, Yamazaki M, Tanabe K, Sawanoi M. Determination of ticlopidine in rabbit plasma by high-performance liquid chromatography. Chem. Pharm. Bull. 1987; 3: 1304.
12. Dal Bo L, Verga F, Marzo A, Ambrosoli L, Poli A. Determination of ticlopidine in human plasma by high-performance liquid chromatography and ultraviolet absorbance detection. J. Chromatogr. B 1995; 2(665): 404.
13. Furlan G, Malusa N, Strohmayer A, Klugmann FB, Decorti G, Candussio L, Klugmann S. Optimised method for determination of ticlopidine in serum by high performance liquid chromatography. Farmaco 1996; 11: 747.
14. Róna K, Ary K, Gachályi B, Klebovich I. Liquid chromatographic method for the determination os ticlopidine in human plasma. J. Chromatogr. B 1996; 693: 393.
15. Desager JP, van Nieuwenhuyze Y, Dricot J, Berger Y, Harvengt C. Pharmacokinetic profile and bioavailability of a new galenic formulation of ticlopidine. Int. J. Clin. Pharmacol. Res. 1990; 4: 247.
16. Lagana A, Bellagamba G, Ascenzo D, Gentili A, Marino A. Evaluation of ticlopidine in human serum and plaque by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. Anal. Chim. Acta 1997; 354: 87.
17. US Food and Drug Administration. Federal Register Part 320: Bioavailability and Bioequivalence Requirements. FDA: Washington, DC, 1985; 154.
18. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum 1993; 19: 6501.